LONZA GRP AG/ADR (OTCMKTS:LZAGY) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of LONZA GRP AG/ADR (OTCMKTS:LZAGY) from a hold rating to a buy rating in a research note published on Saturday, Zacks.com reports. They currently have $59.00 price target on the stock.

According to Zacks, “Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company’s Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. “

Several other research analysts have also weighed in on the stock. UBS Group lowered shares of LONZA GRP AG/ADR from a buy rating to a neutral rating in a research report on Thursday, May 14th. ValuEngine upgraded shares of LONZA GRP AG/ADR from a sell rating to a hold rating in a research report on Tuesday, March 17th. Finally, Morgan Stanley restated an overweight rating on shares of LONZA GRP AG/ADR in a research report on Wednesday, June 24th.

OTCMKTS LZAGY opened at $52.99 on Friday. LONZA GRP AG/ADR has a one year low of $31.93 and a one year high of $53.00. The firm’s fifty day moving average is $49.58 and its two-hundred day moving average is $42.19. The firm has a market cap of $38.80 billion, a PE ratio of 38.68 and a beta of 0.81.


Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system.

Further Reading: Why is cost of goods sold important?

Get a free copy of the Zacks research report on LONZA GRP AG/ADR (LZAGY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LONZA GRP AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LONZA GRP AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.